Central Nervous System Lymphoma: Characteristic Findings on Traditional and Advanced Imaging

SUMMARY: CNS lymphoma consists of 2 major subtypes: secondary CNS involvement by systemic lymphoma and PCNSL. Contrast-enhanced MR imaging is the method of choice for detecting CNS lymphoma. In leptomeningeal CNS lymphoma, representing two-thirds of secondary CNS lymphomas, imaging typically shows leptomeningeal, subependymal, dural, or cranial nerve enhancement. Single or multiple periventricular and/or superficial contrast-enhancing lesions are characteristic of parenchymal CNS lymphoma, representing one-third of secondary CNS lymphomas and almost 100% of PCNSLs. New CT and MR imaging techniques and metabolic imaging have demonstrated characteristic findings in CNS lymphoma, aiding in its differentiation from other CNS lesions. Advanced imaging techniques may, in the future, substantially improve the diagnostic accuracy of imaging, ultimately facilitating a noninvasive method of diagnosis. Furthermore, these imaging techniques may play a pivotal role in planning targeted therapies, prognostication, and monitoring treatment response.

[1]  S. Ng,et al.  Primary Cerebral Lymphoma and Glioblastoma Multiforme: Differences in Diffusion Characteristics Evaluated with Diffusion Tensor Imaging , 2008, American Journal of Neuroradiology.

[2]  C. Katlama,et al.  Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. , 2001, Blood.

[3]  W. Heiss,et al.  The potential of PET/MR for brain imaging , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  H. Urbach,et al.  FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  T Ernst,et al.  MR spectroscopy and diffusion-weighted MR imaging in focal brain lesions in AIDS. , 1997, Neuroimaging clinics of North America.

[6]  L. Chang,et al.  Brain lesions in patients with AIDS: H-1 MR spectroscopy. , 1995, Radiology.

[7]  T. Batchelor,et al.  Clinical features and diagnosis of primary central nervous system lymphoma. , 2005, Hematology/oncology clinics of North America.

[8]  Jon D Wilson,et al.  Primary central nervous system lymphoma. , 2008, Archives of pathology & laboratory medicine.

[9]  C. Calli,et al.  Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors. , 2006, European journal of radiology.

[10]  H. Anton-Culver,et al.  Changes in acquired immunodeficiency syndrome‐related non‐Hodgkin lymphoma in the era of highly active antiretroviral therapy , 2006, Cancer.

[11]  P. Ingrand,et al.  Primary intracerebral malignant lymphoma: report of 248 cases. , 2000, Journal of neurosurgery.

[12]  G. Krol,et al.  Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis , 1995, Annals of neurology.

[13]  A. Espeland,et al.  AIDS-related primary central nervous system lymphoma: a Norwegian national survey 1989–2003 , 2008, BMC Cancer.

[14]  Janet E Olson,et al.  The continuing increase in the incidence of primary central nervous system non‐Hodgkin lymphoma , 2002, Cancer.

[15]  Bahattin Hakyemez,et al.  Evaluation of different cerebral mass lesions by perfusion‐weighted MR imaging , 2006, Journal of magnetic resonance imaging : JMRI.

[16]  R. Bakshi Neuroimaging of HIV and AIDS related illnesses: a review. , 2004, Frontiers in bioscience : a journal and virtual library.

[17]  S. Montoto,et al.  Secondary central nervous system lymphoma: risk factors and prophylaxis. , 2005, Hematology/oncology clinics of North America.

[18]  V. Tronnier,et al.  Distinguishing of primary cerebral lymphoma from high-grade glioma with perfusion-weighted magnetic resonance imaging , 2003, Neuroscience Letters.

[19]  S. Sarubbo,et al.  Potential role of CT perfusion parameters in the identification of solitary intra-axial brain tumor grading. , 2010, Acta neurochirurgica. Supplement.

[20]  P. Mischel,et al.  Lymphomatosis Cerebri Presenting as Rapidly Progressive Dementia , 2007, The neurologist.

[21]  R. Guillevin,et al.  Brain lymphoma: usefulness of the magnetic resonance spectroscopy , 2007, Journal of Neuro-Oncology.

[22]  M. Hadley,et al.  Fifty years of the congress of neurological surgeons: foundations, objectives, and legacies. , 2000, Neurosurgery.

[23]  D. Tampieri,et al.  Imaging in Primary Central Nervous System Lymphoma , 2010, The neuroradiology journal.

[24]  Y. Kasamon,et al.  AIDS-related primary central nervous system lymphoma. , 2005, Hematology/oncology clinics of North America.

[25]  P. Bierman,et al.  Diagnosis and treatment of central nervous system involvement in non-Hodgkin's lymphoma. , 2005, Hematology/oncology clinics of North America.

[26]  M. Thurnher,et al.  Analysis of the utility of diffusion-weighted MRI and apparent diffusion coefficient values in distinguishing central nervous system toxoplasmosis from lymphoma , 2006, Neuroradiology.

[27]  E. Rostrup,et al.  Measurement of brain perfusion, blood volume, and blood‐brain barrier permeability, using dynamic contrast‐enhanced T1‐weighted MRI at 3 tesla , 2009, Magnetic resonance in medicine.

[28]  C. Colosimo,et al.  Brain perfusion CT: Principles, technique and clinical applications , 2007, La radiologia medica.

[29]  F. Iwamoto,et al.  Primary dural lymphomas: a review. , 2006, Neurosurgical focus.

[30]  J. Bailes,et al.  Participation in contact or collision sports in athletes with epilepsy, genetic risk factors, structural brain lesions, or history of craniotomy. , 2006, Neurosurgical focus.

[31]  A. Day,et al.  Lumbar spine injuries in athletes. , 2006, Neurosurgical focus.

[32]  E. Wong Management of Central Nervous System Lymphomas Using Monoclonal Antibodies: Challenges and Opportunities , 2005, Clinical Cancer Research.

[33]  V. Jellús,et al.  Diffusion-weighted MR imaging of intracerebral masses: comparison with conventional MR imaging and histologic findings. , 2001, AJNR. American journal of neuroradiology.

[34]  J. V. van Dijck,et al.  Primary central nervous system lymphomas , 2002, Cancer.

[35]  E. Thiel,et al.  Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients , 2005, Journal of Neuro-Oncology.

[36]  M. Weller,et al.  Ocular manifestation of primary nervous system lymphoma: what can be expected from imaging? , 2002, Journal of Neurology.

[37]  M. Burnett,et al.  Return to contact sports after spinal surgery. , 2006, Neurosurgical focus.

[38]  Wei Chen,et al.  Advances in evaluation of primary brain tumors. , 2008, Seminars in nuclear medicine.

[39]  A Gregory Sorensen,et al.  Technical aspects of perfusion-weighted imaging. , 2005, Neuroimaging clinics of North America.

[40]  A. Twijnstra,et al.  Presenting features and value of diagnostic procedures in leptomeningeal metastases , 1999, Neurology.

[41]  J. Shinoda,et al.  High 123I-IMP Retention on SPECT Image in Primary Central Nervous System Lymphoma , 2003, Journal of Neuro-Oncology.

[42]  G. Sfakianakis,et al.  Use of thallium-201 brain SPECT to differentiate cerebral lymphoma from toxoplasma encephalitis in AIDS patients. , 1994, AJNR. American journal of neuroradiology.

[43]  I. Kanno,et al.  Methionine PET for follow-up of radiation therapy of primary lymphoma of the brain. , 1994, Radiographics : a review publication of the Radiological Society of North America, Inc.

[44]  M. Mut,et al.  Parenchymal lymphoma of the brain on initial MR imaging: a comparative study between primary and secondary brain lymphoma. , 2011, European journal of radiology.

[45]  J. P. Glass,et al.  Leptomeningeal metastasis , 1993, Neurology.

[46]  R. Owen,et al.  CNS prophylaxis in lymphoma: who to target and what therapy to use. , 2006, Blood reviews.

[47]  M. Thurnher,et al.  Primary central nervous system lymphoma in AIDS: a wider spectrum of CT and MRI findings , 2001, Neuroradiology.

[48]  M. Deckert,et al.  Primary CNS lymphoma: clinical presentation, pathological classification, molecular pathogenesis and treatment , 2000, Journal of the Neurological Sciences.

[49]  S. Nie,et al.  Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy , 2008, International journal of nanomedicine.

[50]  G. Jahng,et al.  Added Value and Diagnostic Performance of Intratumoral Susceptibility Signals in the Differential Diagnosis of Solitary Enhancing Brain Lesions: Preliminary Study , 2009, American Journal of Neuroradiology.

[51]  M. Chamberlain,et al.  Treatment of CNS dissemination in systemic lymphoma , 2007, Journal of Neuro-Oncology.

[52]  J. Hoffman,et al.  Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[53]  J. Smirniotopoulos,et al.  Primary central nervous system lymphoma: radiologic-pathologic correlation. , 1997, Radiographics : a review publication of the Radiological Society of North America, Inc.

[54]  M. Hartmann,et al.  Differentiating primary central nervous system lymphoma from glioma in humans using localised proton magnetic resonance spectroscopy , 2003, Neuroscience Letters.

[55]  M. Weller,et al.  MRI features of primary central nervous system lymphomas at presentation , 2001, Neurology.

[56]  A. Espeland,et al.  Increasing incidence and continued dismal outcome of primary central nervous system lymphoma in Norway 1989–2003 , 2007, Cancer.

[57]  T. Naidich,et al.  Central Nervous System Lymphoma Characterization by Diffusion‐Weighted Imaging and MR Spectroscopy , 2008, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[58]  P. Morris,et al.  Therapeutic challenges in primary CNS lymphoma , 2009, The Lancet Neurology.

[59]  A. Espeland,et al.  Diagnostic delay in primary central nervous system lymphoma , 2005, Acta oncologica.

[60]  A. Espeland,et al.  CT and MR Imaging Features of Primary Central Nervous System Lymphoma in Norway, 1989–2003 , 2009, American Journal of Neuroradiology.

[61]  C. Derdeyn,et al.  Effect of intraarterial verapamil on the diameter of vasospastic intracranial arteries in patients with cerebral vasospasm. , 2006, Neurosurgical focus.

[62]  E. Neuwelt,et al.  An exploratory study of ferumoxtran-10 nanoparticles as a blood-brain barrier imaging agent targeting phagocytic cells in CNS inflammatory lesions. , 2005, AJNR. American journal of neuroradiology.

[63]  S. Cha,et al.  Diffusion-Weighted MR Imaging Derived Apparent Diffusion Coefficient Is Predictive of Clinical Outcome in Primary Central Nervous System Lymphoma , 2010, American Journal of Neuroradiology.

[64]  M. R. Patel,et al.  Primary lymphoma of the central nervous system: typical and atypical CT and MR imaging appearances. , 2001, AJR. American journal of roentgenology.

[65]  B. O'neill,et al.  Ocular manifestations and treatment of central nervous system lymphomas. , 2006, Neurosurgical focus.

[66]  P. Hartge,et al.  Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. AIDS/Cancer Study Group. , 1996, Journal of the National Cancer Institute.

[67]  U. Missler,et al.  Neuroradiological findings in primary cerebral lymphomas of non-AIDS patients , 2003, Clinical Neurology and Neurosurgery.

[68]  T. Batchelor,et al.  Primary central nervous system lymphoma: presentation, diagnosis and staging. , 2006, Neurosurgical focus.